We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Drugs for the Treatment of Obesity

Alison Poulton, MA, MBBChir, MD1; Ralph Nanan, DrMedHabil1
[+] Author Affiliations
1Sydney Medical School Nepean, University of Sydney, Sydney, New South Wales, Australia
JAMA. 2014;311(17):1807. doi:10.1001/jama.2014.2104.
Text Size: A A A
Published online


To the Editor The review1 by Dr Yanovski and Dr Yanovski on the treatment of obesity focused on drugs currently approved by the US Food and Drug Administration for long-term treatment, which includes orlistat, phentermine-topiramate, and lorcaserin. The discussion of the mechanisms of action of the latter 2 drugs was limited to their appetite-suppressive effects.

However, these medications also have major psychotropic properties. Phentermine is structurally and functionally similar to dexamphetamine, with similar clinical effects on mood and motivation.2 Topiramate can lead to mood changes, including improvement or worsening of depression.3 Lorcaserin reduces impulsive responses.4


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




May 7, 2014
Susan Z. Yanovski, MD; Jack A. Yanovski, MD, PhD
1Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland
2Section on Growth and Obesity, National Institute of Child Health and Human Development, Bethesda, Maryland
JAMA. 2014;311(17):1807. doi:10.1001/jama.2014.2110.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...